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TO THE EDITOROverexpansion of the
SAPIEN 3 Transcatheter
Heart Valve
A Feasibility StudyThe Edwards SAPIEN 3 (S3) (Edwards Lifesciences Inc.,
Irvine, California) is the latest iteration of the balloon-
expandable transcatheter heart valve (THV) withFIGURE 1 Computed Tomography Images With Cross-Sectional Area
Computed tomography (CT) images with cross-sectional areas of overex
Lifesciences), 23-, 26-, and a 29-mm SAPIEN 3 transcatheter heart valvseveral new features designed to address the limita-
tions of earlier generation devices. An initial feasibility
study performed in Europe and Canada using the SA-
PIEN 3 demonstrated excellent early outcomes with a
30-day mortality rate of 2.1%, a stroke rate of 1%, and a
major vascular complication rate of 4.2% in the trans-
femoral cohort (1). Subsequently, a large registry of
more than 1,500 high- and intermediate-risk patients
demonstrated comparable outcomes in the United
States (2). Similar to the SAPIEN XT, the S3 THV is
currently commercially available in 3 sizes: 23 mm,
26 mm, and 29 mm. Sizing approaches to the SAPIEN
XT valves have already been described (3). This papers of Overexpanded Sapien 3 Transcatheter Heart Valves
panded Edwards SAPIEN 3 transcatheter heart valves (Edwards
e.
FIGURE 2 Sizing Chart for the Edwards SAPIEN 3 Transcatheter Heart Valve
Sizing chart for the Edwards SAPIEN 3 transcatheter heart valve (THV) based on multidetector computed tomography (MDCT)–derived mean
diameter and cross-sectional area of the aortic valve annulus obtained in the systolic and diastolic phases of the imaging. The MDCT annulus
parameters in the diastolic phase of overexpanded 23-, 26-, and 29-mm S3 THVs with the addition of 2, 3, and 4 ml of volume, respectively,
are also provided. A ¼ area; D ¼ diameter; diast. ¼ diastole; P ¼ perimeter; syst. ¼ systole.
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2042provides recommendations for proper sizing and se-
lection of the Edwards S3 THV; in addition, we
describe a novel concept of overexpanding the S3
THV to safely accommodate annulus sizes substan-
tially larger than the commercially available S3 valves.
Barbanti et al. (4) described a strategy of under-
expanding the SAPIEN XT THV by underﬁlling of the
deployment balloon in patients with high-risk features
or in anatomies where the valve was oversized bymore
than 20% to reduce the risk of annular injury. Over-
expansion of the SAPIEN XT is not feasible due to the
frame design and the rigid skirt. Unlike the SAPIEN XT,
the new frame geometry and the outer skirt design of
the S3 THV may allow for undersizing of the THV. A
recent analysis of the PARTNER 2 (Placement of AoRtic
TraNscathetER Valves 2) S3 study demonstrated that
even with undersizing the SAPIEN 3 valve by up to
5%, rates of signiﬁcant paravalvular leakwere low (5).What is unknown is whether the improved seal of the
S3 valve is due exclusively to the outer skirt or whether
overexpansion of the frame plays a role. In addition,
the limits of overexpansion are currently unknown.
In our study consisting of patients with annuli in
the border zone between 2 valve sizes, the 23-, 26-,
and 29-mm S3 valves were intentionally over-
expanded by overﬁlling of the deployment balloon
with 2, 3, and 4 ml of additional volume, respectively.
After deployment, post-implantation computed to-
mography (CT) scans were performed to evaluate the
mean diameter, area, and perimeter of the over-
expanded valve frame for all 3 S3 THV sizes. Figure 1
shows examples with representative CT measure-
ment for the 3 available S3 valve sizes. It is notable
that the inﬂow and outﬂow part of the overexpanded
S3 valves are ﬂared and reach the maximal diameter,
which is w10% larger by area than the stated nominal
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2043size of the THV. One concern with overexpansion is
impairment of proper leaﬂet function, resulting in
signiﬁcant central aortic regurgitation necessitating a
second valve. We, however, saw no signiﬁcant central
insufﬁciency in any of our overexpanded S3 THV
implants; our series from the 2 heart centers in
Munich, Germany, encompassed more than 30 pa-
tients with initial deliberate overexpansion of the
THV and more than 100 patients with subsequent
post-dilation of a nominally deployed THV. S3 was
originally not designed for overexpansion; however,
we believe that the new frame geometry with a higher
frame height and longer leaﬂets allows the S3 to be
overexpanded to accommodate larger annulus sizes
without causing signiﬁcant central aortic insufﬁ-
ciency. It is also important to note that the valve
frame foreshortens more when it is overexpanded,
which may have implications for valve positioning.
Compared with the strategy of choosing the larger
valve size and underdeploying it, the practice of
selecting the smaller THV and overexpanding it, as
noted above, may allow for a very safe and effective
valve implantation with a lower risk of complications
such as annular rupture. Furthermore, overexpanded
THVs are more circular when fully deployed, which
mayhave a positive impact on their durability,whereas
the leaﬂets of the underdeployed valves may interact
with the valve frame, leading to impaired durability.
Figure 2 provides the sizing chart for the S3 THV
along with measurements for an overexpanded valve
based on our current experience. We used measure-
ments obtained during diastole for sizing because of
the better image quality noted during diastole. It is
recommended to use balloon sizing in cases where
the annulus size falls in the “gray zone” between 2
valve sizes. In these gray zone cases, instead of
selecting the larger valve size and underexpanding
the valve, it may be preferable to select the smaller
valve size and overexpand it with the addition of
the pre-deﬁned volume, especially when treating
severely degenerated and/or calciﬁed valves.
With this novel overexpansion concept, patients
with an annulus size of up to 740 mm2 (mean diameter
of 31 mm) and more can be treated safely depending
on the stiffness and degree of calciﬁcation of the
native valve and annulus. It is important to note that
overexpansion is limited by the burst pressure of the
deployment balloon. Rupture of the balloon can in-
crease the risk of embolization and stroke. Therefore,
it is not recommended to add more than 2 to 4 ml of
additional volume to the nominal deployment balloon
volume for the given valve size. The addition of 2
extra ml of volume to the 23-mm, 3 ml to the 26-mm,
and 4 ml to the 29-mm THV correlates with w11% to13% more volume in the deployment balloon for each
valve size. Depending on the ﬁnal diameter desired, it
may also be possible to use less additional volume. In
the future, benchmark tests are needed to conﬁrm the
long-term durability of an overexpanded S3 THV and
viability of this strategy of overexpansion.Anupama Shivaraju, MD
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Calculation of Instantaneous
Wave-Free RatioThe instantaneous wave-free ratio (iFR) is a re-
cently developed invasive index of coronary disease
severity that simpliﬁes stenosis assessment by elimi-
nating the need for vasodilator administration (1–4).
